CDC treats first monkeypox patient with SIGA's smallpox antiviral via expanded access Read more about CDC treats first monkeypox patient with SIGA's smallpox antiviral via expanded access Monkeypox: a neglected old foe Read more about Monkeypox: a neglected old foe UK logs another 104 monkeypox cases as outbreak of rash-causing virus keeps sweeping the country Read more about UK logs another 104 monkeypox cases as outbreak of rash-causing virus keeps sweeping the country Monkeypox in 2022—What Clinicians Need to Know Read more about Monkeypox in 2022—What Clinicians Need to Know SIGA Receives Approval from the FDA for Intravenous (IV) Formulation of TPOXX® (tecovirimat) Read more about SIGA Receives Approval from the FDA for Intravenous (IV) Formulation of TPOXX® (tecovirimat) New Contract Awarded by U.S. Department of Defense for the Procurement of up to Approximately $7.5 Million of Oral TPOXX® Read more about New Contract Awarded by U.S. Department of Defense for the Procurement of up to Approximately $7.5 Million of Oral TPOXX® SIGA Reports Financial Results for Three Months Ended March 31, 2022 Read more about SIGA Reports Financial Results for Three Months Ended March 31, 2022 SIGA Declares Special Dividend of $0.45 Per Share Read more about SIGA Declares Special Dividend of $0.45 Per Share SIGA Technologies to Host Business Update Call on May 5th, 2022 Following Release of First Quarter 2022 Financial Results Read more about SIGA Technologies to Host Business Update Call on May 5th, 2022 Following Release of First Quarter 2022 Financial Results SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2021 Read more about SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2021 Pagination First page « First Previous page ‹ Previous Page 1 Page 2 Current page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next › Last page Last » Subscribe to
CDC treats first monkeypox patient with SIGA's smallpox antiviral via expanded access Read more about CDC treats first monkeypox patient with SIGA's smallpox antiviral via expanded access
UK logs another 104 monkeypox cases as outbreak of rash-causing virus keeps sweeping the country Read more about UK logs another 104 monkeypox cases as outbreak of rash-causing virus keeps sweeping the country
Monkeypox in 2022—What Clinicians Need to Know Read more about Monkeypox in 2022—What Clinicians Need to Know
SIGA Receives Approval from the FDA for Intravenous (IV) Formulation of TPOXX® (tecovirimat) Read more about SIGA Receives Approval from the FDA for Intravenous (IV) Formulation of TPOXX® (tecovirimat)
New Contract Awarded by U.S. Department of Defense for the Procurement of up to Approximately $7.5 Million of Oral TPOXX® Read more about New Contract Awarded by U.S. Department of Defense for the Procurement of up to Approximately $7.5 Million of Oral TPOXX®
SIGA Reports Financial Results for Three Months Ended March 31, 2022 Read more about SIGA Reports Financial Results for Three Months Ended March 31, 2022
SIGA Declares Special Dividend of $0.45 Per Share Read more about SIGA Declares Special Dividend of $0.45 Per Share
SIGA Technologies to Host Business Update Call on May 5th, 2022 Following Release of First Quarter 2022 Financial Results Read more about SIGA Technologies to Host Business Update Call on May 5th, 2022 Following Release of First Quarter 2022 Financial Results
SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2021 Read more about SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2021